ABILITY Diabetes Global: Abluminus DES+ Fails Non-Inferiority to XIENCE Stent in Diabetes
The ABILITY Diabetes Global trial finds the Abluminus DES+ stent fails non-inferiority to the XIENCE everolimus-eluting stent in diabetes, with higher repeat revascularisation and target-lesion failure. PICO summary and commentary.
